Abstract
Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Current Neuropharmacology
Title: Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Volume: 8 Issue: 2
Author(s): Alberto Spalice, Pasquale Parisi, Laura Papetti, Francesco Nicita, Fabiana Ursitti, Francesca Del Balzo, Enrico Properzi, Alberto Verrotti, Martino Ruggieri and Paola Iannetti
Affiliation:
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Abstract: Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Export Options
About this article
Cite this article as:
Spalice Alberto, Parisi Pasquale, Papetti Laura, Nicita Francesco, Ursitti Fabiana, Del Balzo Francesca, Properzi Enrico, Verrotti Alberto, Ruggieri Martino and Iannetti Paola, Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update, Current Neuropharmacology 2010; 8 (2) . https://dx.doi.org/10.2174/157015910791233141
DOI https://dx.doi.org/10.2174/157015910791233141 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Dexmedetomidine: A Review of its Use for the Management of Pain, Agitation, and Delirium in the Intensive Care Unit
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Neurovestibular and Sensorimotor Studies in Space and Earth Benefits
Current Pharmaceutical Biotechnology The Management and Outcomes of Pharmacological Treatments for Tinnitus
Current Neuropharmacology Biochemical Markers of Renal Function
Current Medicinal Chemistry Eidtorial from Editor-in-Chief : [ Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012 ]
Cardiovascular & Hematological Agents in Medicinal Chemistry Histological Alterations in the Testicular Tissue Induced by Sildenafil Overdoses
Drug Metabolism Letters Adrenomedullin: Roles for Structure and Function in Cardiac or Vascular Tissues
Current Hypertension Reviews Current Evidence Regarding Low-carb Diets for The Metabolic Control of Type-2 Diabetes
Current Diabetes Reviews Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects
Current Pediatric Reviews Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Overlooked Issues of Snakebite Management: Time for Strategic Approach
Current Topics in Medicinal Chemistry “The Tools of the Trade” – An Overview of the Pharmacology of the Endocannabinoid System
Current Pharmaceutical Design TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design